Peptide receptor radionuclide therapy (PRRT) is an emerging targeted radiotherapy used in the treatment of neuroendocrine tumors. In PRRT, radiolabeled peptides that target receptors overexpressed on neuroendocrine tumor cells are used to deliver radiation directly to the cancer sites. This allows for a high dose of radiation to be delivered to tumor cells while limiting radiation exposure to normal tissues.
Get a Sample Copy of the Market Research Report (Use Corporate Mail Id for Quick Response) –
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76975
The global PRRT market has seen significant growth in recent years driven by increasing incidence of neuroendocrine tumors and the effectiveness of PRRT as a treatment option. PRRT offers an improved side effect profile compared to traditional chemotherapy and provides durable responses in patients. Favorable reimbursement policies have also supported market growth. However, challenges around radioisotope supply and side effects of therapy pose restraints.
Market Drivers
Rising Neuroendocrine Tumor Incidence
Neuroendocrine tumors arise from neuroendocrine cells throughout the body and can develop in organs like the lungs, pancreas, stomach or small intestine. The incidence of neuroendocrine tumors has been increasing globally over the past few decades. According to estimates, the annual incidence of neuroendocrine tumors in the United States increased from 1.09 per 100,000 people in 1973 to 7.38 per 100,000 people in 2012. The rising incidence of these rare cancers has directly contributed to increased demand for effective targeted treatment options like PRRT.
Effectiveness of PRRT
PRRT has demonstrated significant efficacy in the treatment of neuroendocrine tumors, achieving high response rates and durable remissions. In clinical studies, PRRT with radiolabeled somatostatin analogs has shown response rates of 65-90% in patients with inoperable or metastatic neuroendocrine tumors. The effectiveness of PRRT in controlling tumor growth and relieving symptoms has made it an important treatment option.
Favorable Reimbursement
Reimbursement policies play a key role in market access and uptake for new oncology therapies. In the US and Europe, PRRT using radiolabeled somatostatin analogs like Lutetium-177 (177Lu)-DOTATATE has received favorable reimbursement and regulatory approvals. 177Lu-DOTATATE is approved by the FDA and EMA for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Reimbursement coverage has enabled broader patient access and provider adoption of PRRT.
Market Restraints
Radioisotope Supply Issues
The supply of critical radioisotopes used in PRRT faces challenges. Isotopes like Lutetium-177 have a short half-life and their production relies on only a few nuclear reactors globally. Any disruptions at reactor sites can significantly impact the supply chain. For example, the shutdown of the National Research Universal reactor in Canada in 2016 created shortages of Lutetium-177 in the US. Dependence on limited production sources poses a key restraint.
Side Effects of Therapy
While PRRT offers an improved side effect profile compared to chemotherapy, it can still cause adverse effects. Common short-term side effects include nausea, vomiting and fatigue. Long-term side effects may include low blood cell counts and kidney damage. Around 5% of patients discontinue PRRT due to side effects. Managing side effects requires supportive care and slow administration of radiolabeled peptides, adding to treatment costs and complexity.
Market Segmentation
By Peptide Drug Type
The global PRRT market is segmented based on the peptide drug used for radiolabeling. Key segments include:
Dotatoc (Octreotide): A somatostatin analog that targets sst2 receptors. It is labeled with various beta-emitting radionuclides.
Dotatate (Lanreotide): Another somatostatin analog targeting sst2 receptors, commonly radiolabeled with Lutetium-177 or Yttrium-90.
By Indication
The market is segmented based on the neuroendocrine tumor location treated with PRRT:
Foregut NETs (lungs, thymus)
Midgut NETs (small intestine, pancreas)
Hindgut NETs (colon, rectum)
By End-user
The main end-users of PRRT include:
Hospitals
Cancer Care Centers
Others (Physician offices, clinics)
Regional Market Analysis
North America: The largest regional market due to rising incidence of neuroendocrine tumors, favorable reimbursement, and regulatory approvals for PRRT. The US and Canada dominate the North America PRRT market.
Europe: Major countries include Germany, France, UK, Italy and Spain. Europe accounts for a significant share due to growing acceptance of PRRT and established healthcare systems.
Asia Pacific: Led by China, Japan and India. The Asia Pacific market is expected to grow rapidly with increasing healthcare expenditure, economic growth and demand for advanced cancer therapies.
Rest of the World: Comprising regions like Latin America and Middle East & Africa. These regions offer growth opportunities for PRRT suppliers due to rising cancer burden and improving access to healthcare.
About Us Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact Us
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453